<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>medications for opioid use disorder &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/medications-for-opioid-use-disorder/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Thu, 28 May 2026 20:16:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>medications for opioid use disorder &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>Cutting-Edge Approaches: Empowering Communities Battling the Opioid Crisis</title>
		<link>https://scienmag.com/cutting-edge-approaches-empowering-communities-battling-the-opioid-crisis/</link>
		
		<dc:creator><![CDATA[SCIENMAG]]></dc:creator>
		<pubDate>Thu, 28 May 2026 20:16:30 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[combined opioid treatment approaches]]></category>
		<category><![CDATA[cost-effectiveness of opioid treatments]]></category>
		<category><![CDATA[economic evaluation of opioid interventions]]></category>
		<category><![CDATA[HEALing Communities Study data]]></category>
		<category><![CDATA[health technology assessment opioid research]]></category>
		<category><![CDATA[medications for opioid use disorder]]></category>
		<category><![CDATA[MOUD initiation and retention]]></category>
		<category><![CDATA[naloxone distribution impact]]></category>
		<category><![CDATA[opioid crisis community interventions]]></category>
		<category><![CDATA[opioid overdose prevention strategies]]></category>
		<category><![CDATA[policy-making for opioid epidemic]]></category>
		<category><![CDATA[reducing opioid-related deaths]]></category>
		<guid isPermaLink="false">https://scienmag.com/cutting-edge-approaches-empowering-communities-battling-the-opioid-crisis/</guid>

					<description><![CDATA[The ongoing opioid crisis in the United States continues to impose devastating health and economic burdens on individuals and communities nationwide. Amid this persistent emergency, new research led by Jagpreet Chhatwal, PhD, and Mert Sahinkoc, PhD, at the Center for Health Technology Assessment (CHTA) within Mass General Brigham, offers groundbreaking insights into the cost-effectiveness of [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>The ongoing opioid crisis in the United States continues to impose devastating health and economic burdens on individuals and communities nationwide. Amid this persistent emergency, new research led by Jagpreet Chhatwal, PhD, and Mert Sahinkoc, PhD, at the Center for Health Technology Assessment (CHTA) within Mass General Brigham, offers groundbreaking insights into the cost-effectiveness of community-based interventions designed to reduce opioid overdose and non-overdose deaths. Published in <em>The Lancet Regional Health &#8211; Americas</em>, this study leverages one of the largest datasets from the HEALing Communities Study to simulate intervention outcomes and guide resource allocation with unprecedented precision.</p>
<p>The opioid epidemic’s complexity demands nuanced understanding and precise targeting of interventions. Medications for opioid use disorder (MOUD) such as buprenorphine and methadone, along with naloxone distribution, have proven lifesaving individually. However, communities have lacked comprehensive evidence on how these treatments, particularly when combined, translate into optimal health outcomes relative to their costs. This gap presents a major challenge for policymakers trying to maximize impact amid limited resources.</p>
<p>Central to the new research was a critical, policy-relevant question: what is the comparative effectiveness and economic return when communities invest in increasing the initiation and retention of MOUD alongside expanding naloxone availability? The multidisciplinary team evaluated these interventions alone and in combination across 26 diverse communities located in Massachusetts, New York, and Ohio, capturing urban and rural settings alike. Their approach prioritized realism by incorporating actual community-level data.</p>
<p>Data foundation for this study stems from the HEALing Communities Study (HCS), an ambitious, multi-state collaborative initiative aimed at ending the opioid crisis. Through extensive data collection over multiple years within 67 communities, HCS provides unparalleled granularity on the deployment and effectiveness of evidence-based interventions against opioid use disorder under real-world conditions. This dataset enabled researchers to calibrate a sophisticated simulation framework known as the Opioid Policy Simulation Model (OPSiM).</p>
<p>OPSiM was specifically tailored for 26 selected communities highly impacted by opioid use disorder. This agent-based simulation tracked individual trajectories affected by opioid dependency from 2025 through 2030, modeling six distinct strategic scenarios. These ranged from maintaining existing intervention levels to various combinations of enhanced naloxone distribution, treatment initiation, and retention efforts. By simulating these futures, the research quantified both health outcomes and economic implications from healthcare system and societal perspectives.</p>
<p>Findings from this modeling effort reveal compelling evidence favoring integrative intervention strategies. The combination of improving treatment initiation, treatment retention, and naloxone availability consistently reduced opioid overdose mortality by 15 to 40 percent and decreased non-overdose opioid-related deaths by 7 to 24 percent across the studied communities. Further, this strategy yielded substantial gains in quality-adjusted life years (QALYs), a metric accounting for both quantity and quality of life, ranging from just over one thousand to nearly forty thousand lives improved according to local scale.</p>
<p>A key insight emerging from the study is the cost-effectiveness of improving both initiation and retention in treatment, which proved favorable in every community metric examined. Healthcare expenditures per QALY gained ranged between $12,000 and $91,000, well within the broadly accepted US healthcare benchmark of $100,000. When societal costs—including productivity losses and criminal justice expenses—were factored in, all intervention strategies except for maintaining status quo became not only cost-effective but cost-saving.</p>
<p>Beyond direct health system savings, the societal return on investment was remarkable. For example, despite healthcare costs rising by $416 million in one community for expanded treatment, total societal costs including indirect factors dropped by $2.39 billion, equating to nearly a sixfold return for every dollar spent on treatment. This amplifies the narrative that comprehensive opioid crisis response is not merely a moral imperative but also a financially sound policy decision.</p>
<p>Perhaps most striking is the recognition that non-overdose opioid-related mortality substantially surpasses overdose deaths in almost every community assessed. These deaths—ranging from approximately 240 to 3,000 per 100,000 population—reveal a hidden dimension of the epidemic, one that traditional focus on overdoses alone obscures. This finding necessitates a shift in public health priorities towards broader harm reduction and treatment strategies encompassing the full spectrum of opioid-related health risks.</p>
<p>For patients and their families, the implications are profound. Expanding access to medications and naloxone not only saves lives but also improves long-term health outcomes and social wellbeing. Patients benefit from more sustained treatment engagement, reduced risk of fatal and nonfatal overdoses, and alleviation of associated social harms. Such evidence supports intensified efforts to reduce barriers to treatment access, especially in underserved rural areas.</p>
<p>From a policy standpoint, this study offers a much-needed roadmap for resource allocation. Unlike standardized national mandates, the granular, community-level modeling provides tailored insights that match intervention mixes to local conditions. This enables public health officials and community leaders to deploy interventions that maximize both lives saved and economic benefit, fostering smarter, context-aware responses to the opioid crisis.</p>
<p>Importantly, the findings advocate for comprehensive strategies addressing not only overdose prevention but also the broader consequences of opioid use disorder. Harm reduction, outreach, and treatment retention emerge as pillars of effective intervention. By broadening the lens beyond opioid overdoses alone, the study underscores an urgent need for multi-dimensional public health frameworks informed by robust data and economic modeling.</p>
<p>In conclusion, the collaboration between leading researchers in health technology assessment and community-based public health initiatives illuminates a path forward in combating one of the most entrenched and costly health crises facing the United States. Their rigorous simulation modeling anchored in real-world data sets a new benchmark for how evidence can guide effective, economically sustainable interventions at the community level. As policymakers, healthcare providers, and advocates look to the future, this research provides an indispensable tool for designing smarter, more impactful opioid crisis responses that truly save lives and resources alike.</p>
<p><strong>Subject of Research</strong>: People</p>
<p><strong>Article Title</strong>: Cost-effectiveness of community-based interventions for reducing opioid overdose and non-overdose deaths: simulation modeling of HEALing Communities Study</p>
<p><strong>News Publication Date</strong>: 1-Jul-2026</p>
<p><strong>Web References</strong>:</p>
<ul>
<li><a href="https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00110-9/fulltext">https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00110-9/fulltext</a>  </li>
<li><a href="http://dx.doi.org/10.1016/j.lana.2026.101480">http://dx.doi.org/10.1016/j.lana.2026.101480</a></li>
</ul>
<p><strong>References</strong>:<br />
Chhatwal, J., et al. &#8220;Cost-effectiveness of community-based interventions for reducing opioid overdose and non-overdose deaths: simulation modeling of HEALing Communities Study.&#8221; <em>The Lancet Regional Health &#8211; Americas</em>.</p>
<p><strong>Keywords</strong>: Drug abuse, Substance abuse, Opioid addiction, Heroin addiction, Narcotics addiction, Drug addiction, Substance related disorders, Public health</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">162381</post-id>	</item>
		<item>
		<title>Opioid Treatment&#8217;s Influence on Jail Mental Health Services</title>
		<link>https://scienmag.com/opioid-treatments-influence-on-jail-mental-health-services/</link>
		
		<dc:creator><![CDATA[SCIENMAG]]></dc:creator>
		<pubDate>Sun, 25 Jan 2026 21:44:56 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[dual diagnosis treatment in prisons]]></category>
		<category><![CDATA[impact of MOUD on inmates]]></category>
		<category><![CDATA[improving inmate recovery processes]]></category>
		<category><![CDATA[integration of mental health and substance use treatment]]></category>
		<category><![CDATA[jail mental health services]]></category>
		<category><![CDATA[medications for opioid use disorder]]></category>
		<category><![CDATA[mental health support in carceral settings]]></category>
		<category><![CDATA[opioid crisis and incarceration]]></category>
		<category><![CDATA[opioid use disorder treatment]]></category>
		<category><![CDATA[qualitative study on jail health services]]></category>
		<category><![CDATA[substance use counseling in jails]]></category>
		<category><![CDATA[transformative changes in jail health care]]></category>
		<guid isPermaLink="false">https://scienmag.com/opioid-treatments-influence-on-jail-mental-health-services/</guid>

					<description><![CDATA[The landscape of carceral settings is seeing transformative changes, especially concerning the integration of medications for opioid use disorder (MOUD). A significant study conducted in 13 jails across Massachusetts sheds light on the multifaceted impacts that the implementation of MOUD has on mental health services and substance use counseling within these confined environments. This research, [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>The landscape of carceral settings is seeing transformative changes, especially concerning the integration of medications for opioid use disorder (MOUD). A significant study conducted in 13 jails across Massachusetts sheds light on the multifaceted impacts that the implementation of MOUD has on mental health services and substance use counseling within these confined environments. This research, led by Pivovarova, Friedmann, and Ferguson, explores qualitative findings that could reshape how health services are delivered in carceral facilities, aiming to bridge the gap between substance use treatment and mental health support.</p>
<p>The opioid crisis poses significant challenges, particularly within the incarcerated population, which often grapples with overlapping issues of substance use disorder and mental health conditions. By implementing MOUD, these jails aim to tackle the dual needs of treatment for opioid dependency while addressing the broader spectrum of mental health issues that arise in such settings. The study&#8217;s findings reveal that while the implementation of MOUD is critical, it has profound implications not just for physical health but also for the mental well-being of inmates.</p>
<p>A key finding of this research highlights the perceived benefits of MOUD on the overall atmosphere within the jails. Prisoners reported feeling more hopeful and engaged in their recovery processes once they had access to these medications. Notably, the increased availability of treatment options allowed for a more nuanced understanding of addiction and mental health, leading to a culture of support rather than punishment. This shift represents a significant departure from traditional carceral approaches that often stigmatize those struggling with substance use disorders.</p>
<p>The qualitative data collected from interviews and focus groups reveal that staff members were also affected by the introduction of MOUD. Many corrections officers and healthcare providers noted that the treatment programs fostered a more collaborative environment. By working alongside mental health professionals, they could address inmates&#8217; needs more effectively. This collaboration is crucial in creating a setting where rehabilitation can take precedence over mere incarceration.</p>
<p>Furthermore, the study found that mental health services within the jail systems were often under-resourced or poorly aligned with substance use programs before the implementation of MOUD. The integration of these two domains led to more holistic treatment approaches, encouraging officials to rethink the operational dynamics of health services in prisons. The importance of continuous professional development and training related to addiction treatment was underscored, as staff members became more educated about the complexities of opioid use disorders and their intersection with mental health issues.</p>
<p>Another interesting aspect of this research was the varying perceptions of MOUD&#8217;s effectiveness among different stakeholders. Inmates voiced concerns about medication availability and the adequacy of counseling services. Some reported that while they appreciated having access to medication, they also desired robust support systems that focused on behavioral health alongside pharmacological treatment. This finding illustrates the critical need for a balanced approach that integrates both medication and counseling to meet the comprehensive needs of individuals in jails.</p>
<p>The implications of this study extend beyond jails in Massachusetts. As correctional facilities nationwide grapple with the opioid crisis, the need for evidence-based practices becomes even more pressing. The insights gleaned from this research provide a foundational understanding of how MOUD can be implemented effectively within various correctional frameworks, ultimately guiding policymakers and correctional administrators toward making informed decisions that prioritize inmate health.</p>
<p>Moreover, the need for policy reform to facilitate these changes is paramount. The study advocates for broader access to MOUD and associated mental health services to become a norm rather than an exception in correctional facilities. Such reforms could herald a new era in criminal justice, one where the focus shifts from punitive measures to rehabilitative practices that acknowledge and address the complexities of addiction.</p>
<p>As carceral settings evolve, the integration of MOUD into standard procedures has the potential to reduce recidivism and foster long-term recovery outcomes. By treating opioid use disorders with the same seriousness as any chronic illness, jails can play a vital role in the broader public health landscape. Addressing these issues within the criminal justice system also serves as an acknowledgment of the societal responsibility to support recovery for all individuals, regardless of their circumstances.</p>
<p>In conclusion, the findings outlined in this important research contribute to the ongoing discourse surrounding addiction treatment in the criminal justice system. By shedding light on the perceived impacts of MOUD implementation, this study advocates for a comprehensive, integrated approach to inmate health care, promoting a paradigm shift within carceral environments. The journey is long, yet the positive strides that jails across Massachusetts are taking mark the beginning of a hopeful evolution in treating substance use disorders and mental health issues in the criminal justice sector.</p>
<p>With these insights, there lies an opportunity for advocates, policymakers, and researchers to continue pushing the conversation forward, ensuring that the needs of vulnerable populations are met with dignity and compassion. As we observe the outcomes of these initiatives, it becomes essential to maintain a commitment to research and understand the long-term effects of integrating mental health services with opioid use disorder treatments in jails. The future of carceral health care depends on it.</p>
<p><strong>Subject of Research</strong>: Integration of medications for opioid use disorder (MOUD) in mental health services and substance use counseling in carceral settings.</p>
<p><strong>Article Title</strong>: Perceived impacts of medications for opioid use disorder implementation on mental health services and substance use counseling in carceral settings: qualitative findings from 13 Massachusetts jails.</p>
<p><strong>Article References</strong>: Pivovarova, E., Friedmann, P.D., Ferguson, W. <i>et al.</i> Perceived impacts of medications for opioid use disorder implementation on mental health services and substance use counseling in carceral settings: qualitative findings from 13 Massachusetts jails. <i>Addict Sci Clin Pract</i> <b>21</b>, 11 (2026). https://doi.org/10.1186/s13722-025-00641-3</p>
<p><strong>Image Credits</strong>: AI Generated</p>
<p><strong>DOI</strong>: https://doi.org/10.1186/s13722-025-00641-3</p>
<p><strong>Keywords</strong>: opioid use disorder, carceral settings, mental health services, substance use counseling, qualitative research.</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">130860</post-id>	</item>
		<item>
		<title>Addressing Opioid Addiction in Jails Enhances Treatment Engagement and Lowers Overdose Deaths and Reincarceration Rates</title>
		<link>https://scienmag.com/addressing-opioid-addiction-in-jails-enhances-treatment-engagement-and-lowers-overdose-deaths-and-reincarceration-rates/</link>
		
		<dc:creator><![CDATA[SCIENMAG]]></dc:creator>
		<pubDate>Wed, 10 Sep 2025 21:24:13 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[addressing addiction in correctional settings]]></category>
		<category><![CDATA[FDA-approved opioid medications]]></category>
		<category><![CDATA[improving health outcomes for released inmates]]></category>
		<category><![CDATA[integrating MOUD in correctional facilities]]></category>
		<category><![CDATA[jail-based addiction treatment programs]]></category>
		<category><![CDATA[medications for opioid use disorder]]></category>
		<category><![CDATA[opioid addiction treatment in jails]]></category>
		<category><![CDATA[opioid epidemic impact on communities]]></category>
		<category><![CDATA[post-release outcomes for incarcerated individuals]]></category>
		<category><![CDATA[reducing overdose deaths in prisons]]></category>
		<category><![CDATA[reincarceration rates and opioid use]]></category>
		<category><![CDATA[treatment retention for opioid use disorder]]></category>
		<guid isPermaLink="false">https://scienmag.com/addressing-opioid-addiction-in-jails-enhances-treatment-engagement-and-lowers-overdose-deaths-and-reincarceration-rates/</guid>

					<description><![CDATA[A groundbreaking study published in the New England Journal of Medicine has revealed compelling evidence that administering medications for opioid use disorder (MOUD) within county jails significantly improves post-release outcomes, including treatment retention, reduction in overdose fatalities, and lower reincarceration rates. This research, funded by the National Institute on Drug Abuse and conducted across seven [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>A groundbreaking study published in the New England Journal of Medicine has revealed compelling evidence that administering medications for opioid use disorder (MOUD) within county jails significantly improves post-release outcomes, including treatment retention, reduction in overdose fatalities, and lower reincarceration rates. This research, funded by the National Institute on Drug Abuse and conducted across seven Massachusetts county jails, addresses a critical gap in addiction treatment among incarcerated populations—underscoring jails as pivotal intervention points in the ongoing opioid crisis.</p>
<p>The opioid epidemic continues to ravage communities across the United States, with over 80,000 opioid-related deaths reported in 2024 alone. Individuals with opioid use disorder (OUD) are disproportionately represented in correctional settings, yet only a fraction of jails nationwide offer MOUD. This study highlights the life-saving potential of integrating FDA-approved medications—buprenorphine, methadone, and naltrexone—into jail-based treatment programs, challenging systemic barriers that limit access during incarceration.</p>
<p>Through an extensive analysis of data from 6,400 incarcerated individuals with probable OUD between September 2019 and December 2020, researchers observed that 42% received MOUD while detained. These individuals were markedly more likely to sustain treatment adherence post-release compared to those who did not receive MOUD, with continuation rates at six months post-release reaching nearly 58%. In stark contrast, only 23% of untreated individuals remained engaged in opioid disorder treatment programs, underscoring the efficacy of jail-initiated MOUD.</p>
<p>Importantly, the study documented a striking 52% reduction in fatal opioid overdoses among individuals treated with MOUD while incarcerated. Non-fatal overdoses decreased by 24%, total mortality by 56%, and reincarceration risks dropped by 12% relative to their untreated counterparts. These multifaceted benefits substantiate MOUD as not only a harm reduction tool but a critical strategy that extends beyond clinical treatment to encompass broader social and criminal justice outcomes.</p>
<p>Massachusetts stands at the forefront of this transformative approach due to legislation enacted in 2018 mandating a four-year pilot program to provide comprehensive MOUD in select county jails. This legislation necessitates the continuation of pre-incarceration MOUD treatment, initiation of treatment prior to release, and seamless linkages to community care—addressing discontinuity in care that has historically exacerbated relapse and overdose risk post-release. This structured initiative provided a unique environment to rigorously evaluate the impact of jail-based MOUD programs on a large scale.</p>
<p>Methodologically, the research leveraged cross-sector data integration, combining self-reported information from incarcerated individuals with detailed clinical records, jail administrative data, and public health datasets through the Massachusetts Public Health Data Warehouse. This linkage spans over 35 state databases, allowing for robust monitoring of treatment trajectories, overdose events, mortality, and reincarceration, thereby offering unprecedented insight into longitudinal outcomes associated with jail-based MOUD programs.</p>
<p>Treatment engagement during incarceration proved to be a strong predictor of sustained community treatment adherence. Notably, more than 60% of those who received MOUD in jail initiated community-based treatment within 30 days of release, a rate over threefold higher than those untreated during incarceration. Furthermore, sustained medication adherence was observed in 50% of treated individuals for at least 75% of the first 90 days post-release, illustrating the critical role of jail-based treatment in establishing long-term recovery trajectories.</p>
<p>Buprenorphine was the predominant medication administered, accounting for nearly 68% of MOUD treatments in jail, followed by methadone and naltrexone. This distribution reflects evolving clinical preferences and accessibility, with buprenorphine’s safety profile and ease of administration likely contributing to its widespread use. Future research is needed to delineate differential outcomes by medication type and to optimize individualized treatment protocols within correctional environments.</p>
<p>The authors emphasize the broader implications of their findings, positing jail-based MOUD programs as a model for public health interventions that confront the opioid crisis at one of its most vulnerable junctures. By bridging gaps in treatment continuity, jails evolve from mere holding facilities to critical nodes in national efforts aimed at promoting recovery, reducing mortality, and curtailing cycles of relapse and recidivism that strain communities and criminal justice systems alike.</p>
<p>Despite these advances, MOUD implementation in jails nationwide remains limited, available in only approximately 13% of facilities and frequently restricted to narrowly defined populations such as pregnant women. The study advocates for widespread policy reform to increase MOUD accessibility across jails, thereby reducing systemic inequities and addressing the public health imperative to treat OUD comprehensively within correctional institutions.</p>
<p>This research was conducted in collaboration with the Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) and the Massachusetts Department of Public Health, representing a multifaceted partnership that bridges clinical, public health, and correctional systems. The integration of these diverse perspectives ensures that findings have practical relevance for policymakers, practitioners, and community stakeholders committed to tackling addiction within justice-involved populations.</p>
<p>Looking forward, the study calls for further investigations into generalizability across diverse correctional systems and populations, examining how variables such as demographic factors, local resources, and specific medications influence outcomes. Additionally, research exploring implementation science strategies to streamline MOUD delivery, enhance patient engagement, and support ongoing recovery post-release remains essential to maximize the public health impact of these programs.</p>
<p>In sum, providing MOUD in county jails emerges as a potent intervention to improve health outcomes, reduce mortality, and disrupt cycles of incarceration associated with opioid use disorder. As the opioid epidemic continues to evolve, this evidence-based approach offers a powerful blueprint for transforming criminal justice settings into pivotal arenas for addiction treatment and recovery.</p>
<hr />
<p><strong>Subject of Research</strong>: Medications for opioid use disorder in correctional settings and their impact on post-release outcomes.</p>
<p><strong>Article Title</strong>: Medications for Opioid Use Disorder in County Jails: Outcomes After Release.</p>
<p><strong>News Publication Date</strong>: September 11, 2025</p>
<p><strong>Web References</strong>:</p>
<ul>
<li>New England Journal of Medicine Article: <a href="http://dx.doi.org/10.1056/NEJMsa2415987">http://dx.doi.org/10.1056/NEJMsa2415987</a>  </li>
<li>Massachusetts Public Health Data Warehouse: <a href="https://www.mass.gov/public-health-data-warehouse-phd">https://www.mass.gov/public-health-data-warehouse-phd</a>  </li>
<li>National Institute on Drug Abuse (NIDA): <a href="https://www.nida.nih.gov">https://www.nida.nih.gov</a>  </li>
</ul>
<p><strong>References</strong>:<br />
PD Friedmann, et al. Medications for Opioid Use Disorder in County Jails: Outcomes After Release. New England Journal of Medicine. DOI: 10.1056/NEJMsa2415987 (2025).</p>
<p><strong>Keywords</strong>: Opioid addiction, Medications for opioid use disorder, Jail-based treatment, Overdose prevention, Incarceration, Substance use disorders, Public health interventions, Reincarceration reduction, Buprenorphine, Methadone, Naltrexone, Criminal justice system.</p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">77754</post-id>	</item>
	</channel>
</rss>
